Your browser does not support iframes.
We are constantly looking for new approaches to treat diseases of the central nervous system, such as multiple sclerosis (MS), neurodegenerative diseases, pain and migraine.
Our work in this area builds upon the inherent strength of Teva’s unique makeup. We are integrating the best of our research and development expertise, our innate knowledge from generic and specialty portfolios (including both small molecules and biologics), our delivery system abilities and other advanced technologies. This creates a broad and varied pipeline that aims to address key unmet patient and societal needs.
Multiple sclerosis (MS) is an autoimmune disease that impacts the central nervous system (CNS). The disease triggers an immune response by the body in which it attacks and damages myelin, the substance which surrounds and insulates our nerve fibers or axons. This damage disrupts the ability of parts of the nervous system to communicate, resulting in a wide range of signs and symptoms, including physical, mental, and sometimes cognitive problems.
It is a chronic, often disabling, disease. Symptoms may be mild, such as numbness in the limbs, or severe, such as paralysis or loss of vision. The progress, severity, and specific symptoms of MS are unpredictable and vary from one person to another. In the U.S. today, there are approximately 400,000 people living with MS. In relapsing-remitting MS, the most common form of the disease, a person experiences attacks (also called relapses or exacerbations) of worsening neurologic functioning followed by periods of remission in which partial or complete recovery occurs.
Teva entered the field of MS treatment through the U.S. introduction of Copaxone® (glatiramer acetate) in 1997.
Pain is one of the most significant healthcare problems we face today. It impacts hundreds of millions of people across the world, profoundly affecting their quality of life and costing society countless billions of dollars in treatment along with lost productivity.
Teva is working hard to address this global challenge, and to bring back a measure of quality to the lives of those patients living with pain.
Teva’s extensive pain care franchise includes a range of investigational, approved and marketed treatments for migraine and breakthrough cancer pain.
The impact of Chronic Pain on Patients and Society
*International Association for the Study of Pain
Pain is the most common reason patients go to see the doctor. A recent survey in Europe* found that chronic pain occurs in nearly 20% of adult Europeans and in one third of Americans - an estimated 100 million people.** While chronic pain is a significant health care problem, it is also a major social problem that seriously affects the quality of people’s social and working lives. The impact of pain includes difficulties with basic everyday activities such as walking, dressing and sleeping, and extends to depression, job loss and family breakdown. The treatment of pain is also currently insufficient. The same survey found that very few pain sufferers were managed by pain specialists. In fact, almost 50% received inadequate pain management, and relied on over-the-counter medication. Where patients do have access to chronic pain treatment, they face potential risks including developing drug tolerance, increased sensitivity to pain, and dependence on opioid medications.* International Association for the Study of Pain** The Institute of Medicine (IOM)
Migraine is a complex neurologic disorder, the origin of which cannot be ascribed to a single brain site or mechanism. It is a chronic condition with recurrent episodic attacks lasting 4-72 hours when not treated, characterized by headache and associated symptoms.Fremanezumab is a monoclonal antibody that binds to calcitonin gene-related peptide (CGRP). CGRP causes headaches in migraine patients, and we know that CGRP levels are elevated during migraine. As such, targeting CGRP has the potential to change the way migraine is treated. Fremanezumab is approved under the trade name AJOVY(TM) in the U.S. and has pending regulatory registrations in other countries.
Fremanezumab is additionally being studied in cluster headache and post-traumatic head injury headache.